Low Back Pain - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Low Back Pain - Pipeline Review, H2 2016

Low Back Pain - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Low Back Pain - Pipeline Review, H2 2016
Published Oct 29, 2016
88 pages — Published Oct 29, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain Pipeline Review, H2 2016, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 7, 3, 3 and 2 respectively for Low Back Pain.

Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)

Re

  
Source:
Document ID
GMDHC8615IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Low Back Pain Overview81
Therapeutics Development91
  Pipeline Products for Low Back Pain Overview91
Low Back Pain Therapeutics under Development by Companies102
Low Back Pain Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Low Back Pain Products under Development by Companies151
Low Back Pain Companies Involved in Therapeutics Development1620
  Adynxx, Inc.161
  Aestus Therapeutics, Inc.171
  Array BioPharma Inc.181
  Axsome Therapeutics Inc191
  Boehringer Ingelheim GmbH201
  Egalet Corporation211
  Frontier Biotechnologies Co., Ltd221
  Gador S.A.231
  Grunenthal GmbH241
  Hisamitsu Pharmaceutical Co., Inc.251
  Immune Pharmaceuticals Inc.261
  KPI Therapeutics, Inc.271
  MD Biosciences GmbH281
  Mesoblast Limited291
  Nektar Therapeutics301
  Orion Oyj311
  Pacira Pharmaceuticals, Inc.321
  Pfizer Inc.331
  Stayble Therapeutics AB341
  Sun Pharma Advanced Research Company Ltd.351
Low Back Pain Therapeutics Assessment3610
  Assessment by Monotherapy Products361
  Assessment by Combination Products371
  Assessment by Target382
  Assessment by Mechanism of Action402
  Assessment by Route of Administration422
  Assessment by Molecule Type442
Drug Profiles4634
  (loxoprofen + methocarbamol) Drug Profile461
  AB-001 Drug Profile471
  ARRY-954 Drug Profile481
  ATX-09002 Drug Profile491
  AYX-2 Drug Profile501
  bupivacaine Drug Profile512
  cebranopadol Drug Profile533
  dexmedetomidine hydrochloride Drug Profile562
  Drug for Chronic Low Back Pain Drug Profile581
  HP-3150 Drug Profile591
  IG-8801 Drug Profile601
  lidocaine hydrochloride Drug Profile612
  MD-22 Drug Profile631
  MPC-06ID Drug Profile643
  NKTR-181 Drug Profile673
  oxycodone hydrochloride ER Drug Profile702
  SPARC-1401 Drug Profile721
  tanezumab Drug Profile733
  U-2902 Drug Profile762
  zoledronic acid Drug Profile782
Low Back Pain Dormant Projects802
Low Back Pain Discontinued Products821
Low Back Pain Product Development Milestones834
  Featured News &Press Releases831
    Aug 01, 2016: MesoblastS Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science831
    Jun 22, 2016: Frontier Biotech Reports Primary Endpoint Met in Phase 2 Trial of AB001 In Chronic Low Back Pain841
    Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms841
    Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain852
Appendix872
  Methodology871
  Coverage871
  Secondary Research871
  Primary Research871
  Expert Panel Validation871
  Contact Us871
  Disclaimer881

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Low Back Pain - Pipeline Review, H2 2016" Oct 29, 2016. Alacra Store. May 04, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Low-Back-Pain-Pipeline-Review-H2-2016-2088-16730>
  
APA:
Global Markets Direct - Market Research. (2016). Low Back Pain - Pipeline Review, H2 2016 Oct 29, 2016. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Low-Back-Pain-Pipeline-Review-H2-2016-2088-16730>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.